BLEOMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bleomycin, and when can generic versions of Bleomycin launch?
Bleomycin is a drug marketed by Cipla, Fresenius Kabi Usa, Hikma, Hospira, Meitheal, Pharmachemie Bv, Teva Parenteral, and Teva Pharms Usa. and is included in eight NDAs.
The generic ingredient in BLEOMYCIN is bleomycin sulfate. There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bleomycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bleomycin
A generic version of BLEOMYCIN was approved as bleomycin sulfate by HOSPIRA on March 10th, 2000.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BLEOMYCIN?
- What are the global sales for BLEOMYCIN?
- What is Average Wholesale Price for BLEOMYCIN?
Summary for BLEOMYCIN
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 8 |
| Drug Prices: | Drug price information for BLEOMYCIN |
| DailyMed Link: | BLEOMYCIN at DailyMed |


